Trevi Therapeutics, Inc.
Company Stats
- Market Cap
- $2.0B
- as of Sep 30, 2026
- Shares Outstanding
- 142.5M
- Free Float
- 38.4%
Income Statement
- Operating Income
- -$49.3M
- Net Income
- -$42.8M
- EBITDA
- -$49.2M
Cash Flow
- Free Cash Flow
- -$42.1M
- FCF Yield
- -2.1%
- Owner FCF Yield
- -2.3%
Balance Sheet
- Cash & Equivalents
- $18.9M
Returns & Capital
- SBC, 3Y Avg
- $3.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$42.1M | — |
| FY2024 | — | -$38.3M | — |
| FY2023 | — | -$31.8M | — |
| FY2022 | — | -$28.3M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 31, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges